Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

NCT03592472 is registered in ClinicalTrials.gov with Xynomic Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03592472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03592472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 17, 2018
Completion date
June 30, 2028
Enrollment
413 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma